1. Scrip
  2. >>Business
  3. >>Strategy

PTC Eyes Transition From Capital-Raising To Money-Making Company

 
• By Mandy Jackson

With $1.1bn in cash plus revenue from its existing commercial products and royalties from Roche’s sales of newly approved Evrysdi to invest in R&D, PTC Therapeutics may achieve profitability in 2023.

Businessman accountant counting money and making notes at report doing finances and calculate about cost of investment and analyzing financial data, Financing Accounting Banking Concept.
PTC may be profitable by 2023 based on product sales and royalties • Source: Shutterstock

PTC Therapeutics, Inc. CEO Stuart Peltz told Scrip that with $1.1bn in the bank the company has never been better capitalized to fund its pipeline of rare disease drug candidates. And with royalties from Evrysdi (risdiplam) – newly approved in the US for spinal muscular atrophy (SMA) – and revenue from its existing commercial portfolio plus near- and mid-term product approvals, PTC forecasts that it may generate $1.5bn in revenue by 2023 and achieve profitability.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Roivant Tightens Leadership Grip On Immunovant, Narrows Near-Term IMVT-1402 Focus

 
• By Mandy Jackson

Roivant president Eric Venker was named CEO of Immunovant to guarantee execution of the development plan for IMVT-1402 in six indications, now including Sjögren’s disease and cutaneous lupus erythematosus.

Menarini’s APAC CEO On Harnessing Digital Channels, RWE And BD Engine

 
• By Anju Ghangurde

In the final part of this interview with Scrip, Menarini’s Asia-Pacific CEO talks about the Italian group’s digital capabilities, including the impact made during a shortage issue in Australia, and leveraging RWE to inform healthcare practices across the region. The company is also revving up its business development and alliance engine, with around 14 candidates under evaluation at different stages at the regional level.

Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding Platform

 
• By Jung Won Shin, Lisa Takagi, Joseph Haas, Anju Ghangurde, and Vibha Ravi

Plus deals involving Elix/PRISM, Rege/Syros, Kaken/KalVista, Dr. Reddy’s/Aurigene/Edity, Nissan Chemical/Sanwa, Lupin/Renascience, Shionogi/Link Medicine, Abbisko/Merck & Co., Ono/Reborna and Apollomics/LaunXp.

Cancer Retains Top Spots In Alliance Deal Volume, Value

 
• By Joseph Haas

Cancer assets drove the highest percentage of biopharma alliance dealmaking in 2024, tripling the frequency of the next highest therapeutic category, neurology.

More from Business

Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding Platform

 
• By Jung Won Shin, Lisa Takagi, Joseph Haas, Anju Ghangurde, and Vibha Ravi

Plus deals involving Elix/PRISM, Rege/Syros, Kaken/KalVista, Dr. Reddy’s/Aurigene/Edity, Nissan Chemical/Sanwa, Lupin/Renascience, Shionogi/Link Medicine, Abbisko/Merck & Co., Ono/Reborna and Apollomics/LaunXp.

Cancer Retains Top Spots In Alliance Deal Volume, Value

 
• By Joseph Haas

Cancer assets drove the highest percentage of biopharma alliance dealmaking in 2024, tripling the frequency of the next highest therapeutic category, neurology.

Oncology’s Most Eligible Unpartnered Assets

 
• By Edwin Elmhirst

Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.